Cartalax dosage chart
20 mg Vial
Cartalax is dosed at 2 mg–5 mg daily via subcutaneous injection in educational protocols. A 20 mg vial reconstituted with bacteriostatic water yields about 6.67 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.
- Example daily range
- 2,000–5,000 mcg once daily (gradual titration).
- Easy measuring
- At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U‑100 insulin syringe.
- Storage
- Lyophilized: store at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F) for long‑term; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Route & Frequency:
| Week/Phase | Daily Dose (mcg / mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 2,000 mcg (2.0 mg) | 30 units (0.30 mL) |
| Weeks 3–4 | 3,000 mcg (3.0 mg) | 45 units (0.45 mL) |
| Weeks 5–8 | 4,000 mcg (4.0 mg) | 60 units (0.60 mL) |
| Weeks 9–12 | 5,000 mcg (5.0 mg) | 75 units (0.75 mL) |
Reconstitution steps
- 1Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 2Insert needle through the stopper; let the diluent run slowly down the vial wall to avoid foaming.
- 3Gently swirl or roll until fully dissolved (do not shake).
- 4Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose and site rotation to maintain consistency.
- Evidence caveat: Published human clinical trial data for subcutaneous Cartalax is limited; this protocol extrapolates from preclinical studies and standard peptide handling practices.
How This Works
Cartalax (Ala‑Glu‑Asp) is classified among the Khavinson bioregulatory peptides—ultrashort peptides that may interact with DNA and modulate gene expression at nanomolar concentrations. The peptide sequence corresponds to a motif found in the alpha‑1 chain of type XI collagen, a structural protein important for cartilage integrity. In preclinical fibroblast and chondrocyte culture models, Cartalax has been reported to upregulate Ki‑67 (a proliferation marker), increase SIRT‑1/SIRT‑6 expression, reduce p53 and caspase‑3 activity (pro‑apoptotic signals), and inhibit MMP‑9 synthesis (an enzyme linked to extracellular matrix degradation).
Potential Benefits & Side Effects
Observations from preclinical literature.
- May support fibroblast proliferation and reduce markers of cellular senescence in aged cell cultures.
- Preclinical data suggest modulation of extracellular matrix homeostasis via MMP‑9 inhibition and collagen‑related gene expression.
- General tolerability: Khavinson bioregulator peptides have been described as well tolerated in observational settings; occasional mild injection‑site reactions (redness, itch) may occur with subcutaneous administration.
- Limitations: No large‑scale human RCTs; most data derive from in vitro or rodent models.
Lifestyle Factors
Complementary strategies for best outcomes.
- Support joint and connective‑tissue health with adequate protein, vitamin C, and collagen precursors.
- Combine low‑impact exercise and mobility work to reinforce musculoskeletal adaptations.
- Prioritize sleep and stress management to support tissue repair and recovery.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources.
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
important-note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
Cartalax dosage FAQs
How much bacteriostatic water do you use to reconstitute Cartalax?
Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration. for a 20 mg Vial vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.
What does the Cartalax route & frequency: look like?
Weeks 1–2 — 2,000 mcg (2.0 mg) — 30 units (0.30 mL); Weeks 3–4 — 3,000 mcg (3.0 mg) — 45 units (0.45 mL); Weeks 5–8 — 4,000 mcg (4.0 mg) — 60 units (0.60 mL); Weeks 9–12 — 5,000 mcg (5.0 mg) — 75 units (0.75 mL). The full table above lists every step with matching syringe units.
What are the mixing steps for Cartalax?
Draw 3.0 mL bacteriostatic water with a sterile syringe. Insert needle through the stopper; let the diluent run slowly down the vial wall to avoid foaming. Gently swirl or roll until fully dissolved (do not shake).
How should reconstituted Cartalax be stored?
Storage: Lyophilized: store at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F) for long‑term; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles..
How many insulin syringe units equal a Cartalax dose?
Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.
Is Cartalax approved for human use?
No. Cartalax is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.
Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.
On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.